全ての心停止に対し緊急のインターベンションが必要なわけではない(Abstract 19-LB-20652)

In patients resuscitated after cardiac arrest who do not show evidence of ST-segment elevation myocardial infarction (STEMI), receiving immediate coronary angiography did not improve survival at 90 days compared to waiting a few days before undergoing the procedure, based on findings presented at the American College of Cardiology's 68th Annual Scientific Session.

For people who are resuscitated from cardiac arrest due to STEMI, it is common practice to immediately proceed with coronary angiography.  If blockages are found, the medical team inserts a stent.  However, it has been unclear whether this practice is beneficial for people who suffer cardiac arrest without STEMI. This study is the first randomized controlled trial to shed light on the optimal timing of coronary angiography in these patients.

"It is an important trial for the entire cardiac arrest team," said Jorrit Lemkes, MD, a cardiologist at Amsterdam University Medical Centre in the Netherlands and the study's lead author. "The question of whether or not to immediately send the patient for catheterization comes up routinely in this group of patients. This trial gives us more information on that question, suggesting patients who do not show ST- segment elevation on the electrocardiogram do not require an immediate invasive strategy after cardiac arrest."

The trial enrolled 552 patients who were treated at 19 medical centers in the Netherlands after suffering cardiac arrest outside of a hospital. All patients were evaluated with an electrocardiogram upon arrival at the emergency department and found not to have evidence of STEMI. Half of the patients were randomly assigned to immediately proceed to the cardiac catheterization laboratory, where they underwent coronary angiography and subsequent PCI if needed. The other half was transferred to the intensive care unit for standard post-resuscitation care. These patients underwent coronary angiography and PCI, if needed, only after they awoke and showed signs of neurological recovery, which typically occurs after a few days.

The results showed no significant difference between the two groups in terms of survival at 90 days, the trial's primary endpoint. Survival was better than expected in both groups, with 64.5 percent of those receiving immediate intervention and 67.2 percent of those receiving delayed intervention alive 90 days after their cardiac arrest. Researchers say the findings may reflect the fact that clearing the arteries with PCI sooner after cardiac arrest does not necessarily reduce the likelihood of long-term brain damage, which is a key factor in survival after cardiac arrest.

"We'd hoped that sending these patients for immediate catheterization would improve outcomes, but I think there are some explanations for why we found what we found," Lemkes said. "One is that the primary cause of death in this patient group is neurological injury, and it is difficult to imagine how immediate catheterization would address that."

Previous trials have suggested cooling the body can improve outcomes for patients after cardiac arrest. An analysis of secondary outcomes revealed patients who received delayed intervention achieved the target body temperature more quickly, after an average of 4.7 hours compared to 5.4 hours in the group receiving immediate intervention. However, this trend did not translate to a significant survival benefit.

The timing of angiography did not appear to make difference in regard to other secondary outcomes relevant to the degree of brain damage, kidney problems, bleeding and other common complications after cardiac arrest.

Lemkes said that the study's moderate sample size and the higher-than-expected survival rate may have limited the study's statistical power. In addition, the trial's findings are relevant only to non-STEMI patients after cardiac arrest, not to STEMI patients or those experiencing cardiogenic shock. He added that the results of several other ongoing trials may shed more light on the optimal timing of angiography in non-STEMI patients or help to identify subgroups who may be more likely to benefit from immediate intervention.

The study received funding from Biotronik, AstraZeneca and the Netherlands Heart Institute.

This study was simultaneously published online in the New England Journal of Medicine at the time of presentation.